Could Accelerate Diagnostics Incorporated (NASDAQ:AXDX) See a Reversal After More Sellers Came In?

December 7, 2017 - By Peter Erickson

 Could Accelerate Diagnostics Incorporated (NASDAQ:AXDX) See a Reversal After More Sellers Came In?

Investors sentiment increased to 3 in 2017 Q2. Its up 1.63, from 1.37 in 2017Q1. It is positive, as 10 investors sold Accelerate Diagnostics, Inc. shares while 13 reduced holdings. 25 funds opened positions while 44 raised stakes. 19.15 million shares or 2.80% less from 19.70 million shares in 2017Q1 were reported.
Zurcher Kantonalbank (Zurich Cantonalbank) has 956 shares for 0% of their portfolio. Albion Financial Group Ut holds 0.26% or 58,278 shares in its portfolio. Oaktop Cap Ii Ltd Partnership reported 0.78% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Voya Investment Ltd holds 0% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 12,193 shares. California State Teachers Retirement Systems stated it has 46,111 shares. Nuveen Asset Management Ltd Liability Company holds 0.12% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) or 672,722 shares. 55,900 were reported by Swiss Bancshares. Barbara Oil accumulated 9,000 shares. Tower Research Capital Lc (Trc), a New York-based fund reported 2,184 shares. Neuberger Berman Gp Ltd Liability Com reported 13,550 shares. Moreover, Barclays Public Limited Co has 0% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 5,132 shares. Credit Suisse Ag holds 0.02% or 883,173 shares. Tiaa Cref Mgmt Ltd Liability Com reported 0% stake. 25,552 were accumulated by Stifel Fincl. Geneva Advisors Ltd has 0.02% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX).

The stock of Accelerate Diagnostics Incorporated (NASDAQ:AXDX) registered an increase of 3.6% in short interest. AXDX’s total short interest was 11.15M shares in December as published by FINRA. Its up 3.6% from 10.76 million shares, reported previously. With 440,800 shares average volume, it will take short sellers 25 days to cover their AXDX’s short positions. The short interest to Accelerate Diagnostics Incorporated’s float is 46.95%.

The stock increased 4.06% or $1.1 during the last trading session, reaching $28.2. About 250,976 shares traded. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has risen 147.12% since December 7, 2016 and is uptrending. It has outperformed by 130.42% the S&P500.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. The company has market cap of $1.56 billion. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. It currently has negative earnings. The firm was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Ratings Coverage

Among 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Accelerate Diagnostics had 8 analyst reports since August 25, 2015 according to SRatingsIntel. The company was initiated on Wednesday, December 16 by Piper Jaffray. The stock of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has “Overweight” rating given on Tuesday, August 9 by JP Morgan. The rating was maintained by Piper Jaffray on Sunday, September 17 with “Buy”. The rating was initiated by William Blair on Friday, January 8 with “Outperform”. The stock has “Neutral” rating by BTIG Research on Tuesday, August 25. JP Morgan initiated it with “Overweight” rating and $17 target in Thursday, March 24 report. The firm has “Buy” rating by Piper Jaffray given on Thursday, August 3. The stock has “Buy” rating by BTIG Research on Wednesday, July 12.

More news for Accelerate Diagnostics, Inc. (NASDAQ:AXDX) were recently published by: Globenewswire.com, which released: “Accelerate Diagnostics to Present at the 29th Annual Piper Jaffray Healthcare …” on November 15, 2017. Zacks.com‘s article titled: “Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher November 16, 2017” and published on November 16, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: